FDA "plans November biosimilars law meeting"
This article was originally published in Scrip
Executive Summary
Reports are circulating in Washington, DC that the FDA will soon announce in the Federal Register a two-day public meeting for early November to obtain input on specific issues associated with implementing the biosimilars approval pathway, which was passed by Congress earlier this year with US healthcare reform, but there has been no official confirmation.